

Data Sheet

Product Name: Ningetinib
Cat. No.: CS-0027542
CAS No.: 1394820-69-9
Molecular Formula: C31H29FN4O5


Molecular Weight: 556.58

Target: c-Met/HGFR; TAM Receptor; VEGFR

Pathway: Protein Tyrosine Kinase/RTK

Solubility: H2O: < 0.1 mg/mL (insoluble); DMSO: 16.67 mg/mL (29.95

mM; Need ultrasonic)



BIOLOGICAL ACTIVITY:

Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and AxI, respectively. IC50 & Target: VEGFR, c-Met, and $AxI^{[1]}$ In Vitro: Ningetinib is a potent, orally bioavailable small molecule tyrosine kinase inhibitor (TKI) with IC₅₀s of 6.7, 1.9 and <1.0 nM for c-Met, VEGFR2 and AxI, respectively. In cell-based functional assays, Ningetinib (CT053PTSA) inhibits HGF and VEGF-stimulated HUVEC proliferation and microvascular angiogenesis in rat aortic rings with IC₅₀ values of 8.6 and 6.3 nM, respectively^[1]. In Vivo: When single dosed orally (3 mg/kg) to U87MG tumor-bearing nude mice, Ningetinib (CT053PTSA) potently inhibits the phosphorylation of c-Met and its downstream signaling kinases AKT and ERK1/2 for up to 6 hours in tumor tissues. In orthotopic U87MG human glioblastoma xenograft model, Ningetinib prolongs the median survival time (MST) and yields significant increase in life-span value (ILS=32%, p=0.003) at an oral dose of 20 mg/kg/day (dosed 21 days) versus the vehicle-treated group^[1].

References:

[1]. Ning Xi, et al. Abstract 1755: CT053PTSA, a novel c-MET and VEGFR2 inhibitor, potently suppresses angiogenesis and tumor growth. Cancer Res 2014;74(19 Suppl):Abstract nr 1755.

CAIndexNames:

 $1 \\H-Pyrazole-4-carboxamide, N-[3-fluoro-4-[[7-(2-hydroxy-2-methylpropoxy)-4-quinolinyl]oxy] phenyl]-2, \\3-dihydro-1, \\5-dimethyl-3-oxo-2-phenyl-4-quinolinyl]oxy] phenyl]-2, \\3-dihydro-1, \\5-dimethyl-3-oxo-2-phenyl-4-quinolinyl]oxy] phenyl]-2, \\3-dihydro-1, \\3-dimethyl-3-oxo-2-phenyl-4-quinolinyl]oxy] phenyl]-2, \\3-dimethyl-3-oxo-2-phenyl-4-quinolinyl]oxy] phenyl]-2, \\3-dimethyl-3-oxo-2-phenyl-4-quinolinyl]oxy] phenyl]-2, \\3-dimethyl-3-oxo-2-phenyl-4-quinolinyl]oxy] phenyl-3-quinolinyl[3-dimethyl-3-oxo-2-phenyl-4-quinolinyl]oxy] phenyl-3-quinolinyl[3-dimethyl-3-oxo-2-phenyl-4-quinolinyl[3-dimethyl-3-oxo-2-phenyl-4-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimethyl-3-quinolinyl[3-dimet$

SMILES:

CC1 = C(C(NC2 = CC(F) = C(OC3 = CC = NC4 = C3C = CC(OCC(C)(O)C) = C4)C = C2) = O)C(N(C5 = CC = C5)N1C) = O(C3 = C4) = C4)

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 732-484-9848 Fax: 888-484-5008 E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA

Page 1 of 1 www.ChemScene.com